Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$13.1M
25M shares
52-week range
$0.46 – $1.55
10% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $433.3K | $222.6K | $384.5K | $722.7K | $255.4K | $226.2K | $464.3K | $705.9K |
| Cost of revenue | $25.2K | $22.9K | $99.4K | $175.3K | $71.8K | $31.5K | $4.8K | $2.7K |
| Gross profit | $408.1K | $199.7K | $215.4K | $547.4K | $183.6K | $194.7K | $459.5K | $703.2K |
| Gross margin | 94.2% | 89.7% | 56.0% | 75.7% | 71.9% | 86.1% | 99.0% | 99.6% |
| R&D | $492.9K | $555.7K | $387.1K | $1.3M | $1.8M | $3.7M | $2.4M | $8.2M |
| Operating income | −$6.6M | −$4.1M | −$4.1M | −$5.7M | −$6.6M | −$6.5M | −$5.8M | −$11.9M |
| EBITDA | −$6.6M | −$4.0M | −$4.0M | −$4.0M | −$7.3M | −$6.6M | −$5.7M | −$11.8M |
| Net income | −$6.6M | −$4.1M | −$3.9M | −$4.0M | −$7.3M | −$6.7M | −$5.8M | −$11.9M |
| Net margin | -1523.0% | -1841.5% | -1023.0% | -557.2% | -2846.3% | -2946.4% | -1248.2% | -1686.0% |
| EPS (diluted) | -2.79 | -1.62 | -1.42 | -0.92 | -1.24 | -1.01 | -0.47 | -0.66 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $200000 | $-0.26 | $-0.29–$-0.23 | 1 |
| 2027 | $1M | $-0.31 | $-0.35–$-0.27 | 1 |
| 2028 | $2M | $-0.28 | $-0.32–$-0.24 | 1 |
| 2029 | $70M | $1.34 | $1.17–$1.51 | 1 |
Forward consensus · source: Financial Modeling Prep
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
www.lexariabioscience.comNo one on the platform currently holds LEXX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 16,300 | $12.7K |
No one on the platform has traded LEXX yet.
| $30M |
| — |
| CLSDClearside Biomedical, Inc. | $0.41 | +0.00% | $2M | — |
| CRISCuris, Inc. | $0.44 | +37.69% | $6M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 15.0× sales vs its 46.3× historical median P/S.
Fair value ≈ $1.76 · price $0.57 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$LEXX Why are you guys still listening to MM? He has been wrong about *literally* every single LEXX prediction he made.
View on StockTwits ↗$LEXX anyone saw where the volume went?...is missing for a few days now...hope we gonna see him back!
View on StockTwits ↗$LEXX from now on SP will slowly hike imho... sweet will b.
View on StockTwits ↗$LEXX Moving Lexaria’s DehydraTECH to a 5-week steady-state tablet format tackles Big Pharma’s biggest hurdles: erratic absorption and terrible side effects. Commercial oral GLP-1 tablets work by adhering to the stomach lining. By matching this form factor, DehydraTECH should flatten wild patient-to-patient blood variations and deliver highly uniform bioavailability. Furthermore, past data shows Lexaria cuts gastrointestinal side effects by up to 50%. Over 5 weeks, avoiding sharp daily drug spikes will prove DehydraTECH offers superior long-term tolerability. If the data confirms a smooth, highly uniform steady-state blood graph in a plug-and-play tablet format, it removes the final manufacturing risks keeping Big Pharma licensing dollars on the sidelines. Should continue to rally now until data readout Aug/September and potential the most exciting period for this company in its history. $LLY $NVO $PFE $SUNPHARMA.NSE
View on StockTwits ↗$LEXX The main event is late July to Early August 2026: Final steady-state data drops for Human Pilot Study #7 (GLP-1-H26-7). Dosing began June 14th and wraps up its 5-week schedule on July 19th. If you look at this strictly from the perspective of what a multi-billion dollar M&A or business development board cares about, Human Pilot Study #7 (the head-to-head vs. commercial Wegovy tablets) is the absolute holy grail. So we could see early signs of MTA action as early as August. While the animal studies are great for expanding the future pipeline, Study #7 is the exact gatekeeper for Lexaria's immediate valuation and the ultimate catalyst for a Big Pharma deal. The other two studies are expected as follows: Mid-to-Late Summer 2026: Unblinded pharmacokinetic (PK) results for Animal Study #2 (GLP-1-A26-2). Early September 2026: Final unblinded readouts for the massive 11-arm Animal Study (GLP-1-A26-1). Pointing to a very exciting fall.
View on StockTwits ↗$LEXX The market will churn until datasets come out July, August, and September, and then if data hits, we could go into a licensing bidding war. If we strike a $10–20M upfront payment with $100M+ in potential backend milestones and tiered royalties, then the re-rate could be a massive jump from our current $13.5M market cap straight to a $100M+ valuation, launching the share price from $0.54 into a stable $4.00 to $6.00 range overnight. Warrants cash in, treasury is full, short thesis evaporates, RS off the table. First data set is due out in the next 20 trading…
View on StockTwits ↗$LEXX Come on fuckers give me my 55s 😂
View on StockTwits ↗$LEXX So I guess BIO drummed up alot of interest 😂 hope the Wine was good.
View on StockTwits ↗$LEXX With an accumulated deficit of $66,500,000 we (the shareholders) could have bought this instead of funding Lexaria.
View on StockTwits ↗$LEXX All sounds good MM, but way overdue. Still need to get some more study results, to confirm this is the most undervalued play of the century. But it's going to take a lot more than 4,500 shares in an hour to make this happen. Speculation is near non existent at this juncture. That's gotta tell you something on timing.
View on StockTwits ↗$LEXX Our CEO at InVivo Therapeutics was involved in the company's collapse before coming to Lexaria—it’s all public record. We have a CEO who drove the stock to all-time lows, and judging by his past, he doesn't seem capable of holding the role... Who chose him, and why? Aside from collecting salaries and bonuses, he doesn't seem qualified or up to the task.
View on StockTwits ↗$LEXX Cool, gap closed from Friday. Can we get a rally going?
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.